Understanding kidney failure
The kidneys are the body's precision filter: they remove waste and excess fluid, balance sodium and potassium, and help control blood pressure. When damage reduces that filtering capacity below roughly 15% of normal — end-stage kidney disease — the body cannot stay in balance without support, and renal replacement therapy becomes necessary.
In India, the two dominant causes are diabetes and high blood pressure. Both do damage silently, over a decade or more, and both are rising in urban working populations — the exact demographic that often reaches a specialist only after symptoms force the visit.
That is why the diagnosis is usually a surprise. Fatigue, swelling in the feet or face, nausea, appetite loss, cramps and trouble concentrating are the classic late symptoms — but they arrive late precisely because kidneys tolerate enormous damage invisibly. The single most protective habit an adult can adopt is an annual creatinine and urine test if you are diabetic or hypertensive.
Two everyday culprits deserve attention in urban households. Regular over-the-counter painkillers from the NSAID family can quietly damage kidneys when used for months for joint or back pain. And untreated or loosely-controlled blood pressure — the classic "tension patient" who skips daily tablets — is the most common reversible driver of progression. If a parent has diabetes, hypertension or known kidney disease, the information is transmitted twice over: genetically, and through family habits of diet, salt and medication discipline.
Stages, tests, and what they mean
Chronic kidney disease is graded in five stages by a single blood number: eGFR, estimated glomerular filtration rate. Stage 1 is damage with normal filtration; stage 2 is mild; stage 3 is moderate; stage 4 severe; stage 5 is kidney failure. The urine albumin test catches protein leakage — often the earliest signal.
Your nephrologist treats the stage, not the number. Early stages focus on blood pressure, sugar control, salt and medicines that protect the kidneys. Later stages add diet discipline, anaemia management, bone-mineral balance and — at the right moment — the transplant conversation. You will hear the word "creatinine" constantly; it is the raw value behind eGFR, and tracking its trend matters more than any single reading.
Monitoring cadence is part of the treatment. Most stable patients are seen every three to six months, with blood and urine checks at each visit; advanced stages tighten to monthly or weekly review. Families that keep a simple spreadsheet of "date — creatinine — eGFR — blood pressure — medicine list" arrive at consultations dramatically better informed than those who carry a bag of unordered reports. It costs ten minutes a visit and changes the quality of every decision that follows.
When a transplant is considered
Two treatments stand in for failed kidneys: dialysis and transplant. Both work. A transplant is different because it restores near-normal function instead of substituting for it, and for most eligible patients it offers the best long-term survival, fewer dietary restrictions and freedom from the dialysis clock.
The transplant question is therefore asked when three things line up: advanced kidney failure, general health good enough for surgery, and a realistic donor plan. Someone with an active serious infection or advanced heart disease may not qualify — the team verdict is individual, never generic.
The evaluation process
Evaluation is deliberately rigorous because it protects both the recipient and the donor. Expect blood group and tissue typing, heart and lung checks, infection screening, and a psychological and social assessment of your commitment to lifelong medication.
Two phrases will appear in the reports and deserve understanding. HLA typing compares the genetic markers your immune system uses to recognise tissue; closer matches lower rejection risk. The cross-match is a literal test mixing your blood with donor cells to see whether your immune system would immediately attack — a positive cross-match rules out that donor. Finding an obstacle during evaluation is a win, not a setback: it means the problem surfaced before surgery, where it matters.
Living and deceased donors
A living donor is a healthy person who volunteers one of two kidneys — most often a close relative. A deceased donor is a brain-dead person whose organs are shared through the state and national registries.
Living donation dominates in India — it is planned, fast and generally yields the best outcomes — which is exactly why the law surrounds it with scrutiny. The donor is evaluated separately, must never be paid, and can withdraw at any point without pressure. Families should treat donor counselling as sacred: the decision must come from the donor, not from obligation.
The law in India
The Transplantation of Human Organs and Tissues Act governs every transplant in India. Its principles: donation is voluntary, organ trading is a crime, and near relatives — parents, children, siblings, spouses — receive priority for living donation.
Every living transplant is reviewed by a hospital authorisation committee, and non-near-relative cases by a state committee. This two-layer check exists to shut down unethical commerce and protect donors. For deceased donation, NOTTO and the state registries match and allocate organs, and donation after death remains the greatest single opportunity to close India's transplant gap — one family's donation can save or transform several lives.
The transplant surgery
Donor nephrectomy is usually minimally invasive today — smaller incisions, faster donor recovery. In the recipient, the donated kidney is placed in the lower abdomen and connected to blood vessels and the bladder; the failed native kidneys are typically left in place.
The operation commonly runs three to six hours. Many recipients start producing urine immediately — the first concrete signal the kidney is alive — and the hospital stay is usually about a week, during which immunosuppression is balanced against daily kidney function checks.
In that first week the transplant team builds the exact combination of anti-rejection medicines your body will live with. High doses taper down as your own risk profile becomes clear; blood levels of the medicines are measured so the doses stay in a therapeutic window — too low invites rejection, too high invites infection. Most recipients feel better within days because the body finally rids itself of everything the failed kidneys could not — but the discipline of the first year, not the surgery itself, is what decides the first-decade result.
Recovery and lifelong follow-up
The first year is the most demanding: follow-up visits start weekly and spread out gradually, with regular blood tests watching kidney function, medicine levels and infection markers. Most patients return to normal activity in about two months and to desk work soon after.
Diet relaxes after dialysis, but salt remains the quiet enemy, and weight and new-onset diabetes are the two long-term problems to fight. Vaccination schedules shift around surgery by design. The operational rules are ordinary: daily walking, hygiene, vaccination cadence, and this iron law — if you ever feel unwell with fever, report it the same day rather than waiting for a scheduled visit.
Risks and their management
A balanced guide states the risks plainly. Rejection is the body's immune response to the new kidney; it is detected early by blood tests and usually reversible with medication changes. Infection is more likely under immunosuppression and is managed by prevention and prompt treatment. Surgical complications — bleeding, clotting, bladder-connection problems — are handled by the team. Long-term medication effects on blood pressure, sugars and bones are monitored with routine checks.
The most common cause of a transplant failing years later is hauntingly simple: stopping the medication. Everything else on this page is secondary to that habit — never skip a dose, never miss a follow-up.
Cost and coverage: CGHS, ECHS and insurance
Urban Indian families typically do not leave kidney care to chance — they plan it around coverage. The honest baseline: transplant costs in India are widely reported to range between roughly ₹5 lakh and ₹15 lakh for surgery and initial care, with real variation by city, hospital, donor work-up and medicines. Immunosuppressants continue as a permanent monthly line item.
Coverage differs by your class of insurance. CGHS covers transplant and dialysis for eligible central-government beneficiaries, but only at empanelled hospitals and through its referral and pre-authorisation process. ECHS serves armed-forces families under its own empanelment. Corporate TPA plans vary by employer and policy. Ayushman Bharat — PM-JAY — extends up to ₹5 lakh per family per year for eligible households in participating states, with state-level rule changes over time.
The protective habit, in every case, is the same: secure a written estimate from the hospital, confirm empanelment and coverage in writing before admission, and keep pre-authorisation on time. Our insurance and schemes guide walks through CGHS, ECHS, corporate TPA and Ayushman Bharat step by step, including exactly what to check so you are never caught by a surprise bill.
Two budget realities fix most families. First, the transplant bill is only part of the cost: donor work-up, the first year of immunosuppressants and repeated monitoring visits carry their own weight, and an honest hospital will show you a projected one-year and five-year picture before you commit. Second, private insurance behaves differently from schemes — individual policies carry waiting periods (commonly up to two to four years for pre-existing conditions) and specific transplant limits, so the policy period you are on matters as much as the policy itself. Where a scheme route exists, it is almost always the more economical path; where it does not, a well-chosen private policy is a documented safety net worth buying before the need arises.
Deciding as a family
Kidney care in India is a family system, not a solo patient's journey — donors, finances and daily help all live in the family unit. Decisions work best when information is shared openly: bring two people to consultations, write questions down in advance, keep one folder of reports, and give the would-be donor genuine space to decide freely.
This guide exists so that those family conversations are built on the same facts — not on fear, rumour or a single rushed opinion from an anxious waiting room. Read, discuss, then ask your care team the questions this page leaves unanswered; the right team will answer them without impatience.